{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:55:28Z","timestamp":1793922928682,"version":"4.8.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gim.2023.100870","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T05:03:26Z","timestamp":1690261406000},"page":"100870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"25","author":[{"given":"Helen","family":"Hanson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Astiazaran-Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Amendola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Balma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Klugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ngeow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Schmutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoleta","family":"Voian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra J.","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5395","key":"10.1016\/j.gim.2023.100870_bib1","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","article-title":"Linkage of ATM to cell cycle regulation by the Chk2 protein kinase","volume":"282","author":"Matsuoka","year":"1998","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2(\u2217)1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat Genet"},{"issue":"5449","key":"10.1016\/j.gim.2023.100870_bib3","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line\u00a0hCHK2 mutations in Li-Fraumeni syndrome","volume":"286","author":"Bell","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib4","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/humu.10136","article-title":"Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome","volume":"20","author":"Sodha","year":"2002","journal-title":"Hum Mutat"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jmg.2007.054700","article-title":"Is CHEK2 a cause of the Li-Fraumeni syndrome?","volume":"45","author":"Evans","year":"2008","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-009-0540-9","article-title":"Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort","volume":"121","author":"McInerney","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-009-9269-1","article-title":"Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations","volume":"8","author":"Kaufman","year":"2009","journal-title":"Fam Cancer"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib9","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1158\/0008-5472.CAN-07-5187","article-title":"Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41436-021-01109-w","article-title":"Taking an antiracist posture in scientific publications in human genetics and genomics","volume":"23","author":"Brothers","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2023.100870_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cancergen.2020.07.001","article-title":"Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing","volume":"246-247","author":"Sutcliffe","year":"2020","journal-title":"Cancer Genet"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmedgenet-2018-105872","article-title":"Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report","volume":"56","author":"Spurdle","year":"2019","journal-title":"J\u00a0Med Genet"},{"issue":"34","key":"10.1016\/j.gim.2023.100870_bib13","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","article-title":"Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing","volume":"34","author":"Balma\u00f1a","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/humu.23728","article-title":"Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system","volume":"40","author":"Delimitsou","year":"2019","journal-title":"Hum Mutat"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib16","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/ijc.32385","article-title":"Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer","volume":"145","author":"Kleiblova","year":"2019","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41436-018-0276-1","article-title":"Correction: DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes","volume":"21","author":"Richardson","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1039\/C8MO00137E","article-title":"Integrative data fusion for comprehensive assessment of a novel CHEK2 variant using combined genomics, imaging, and functional-structural assessments via protein informatics","volume":"15","author":"Hines","year":"2019","journal-title":"Mol Omics"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1158\/0008-5472.CAN-21-1845","article-title":"Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk","volume":"82","author":"Boonen","year":"2022","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41431-018-0285-1","article-title":"Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics","volume":"27","author":"Carrieri","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41436-018-0391-z","article-title":"Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"David","year":"2019","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41436-019-0478-1","article-title":"Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Deignan","year":"2019","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib23","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.gim.2022.05.002","article-title":"Reclassification of clinically detected sequence variants: framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)","volume":"24","author":"Loong","year":"2022","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/s41436-020-01065-x","article-title":"Does the law require reinterpretation and return of revised genomic results?","volume":"23","author":"Clayton","year":"2021","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41436-019-0679-7","article-title":"Is there a duty to reinterpret genetic data? The ethical dimensions","volume":"22","author":"Appelbaum","year":"2020","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib26","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/gim.2015.194","article-title":"Recontact in clinical practice: a survey of clinical genetics services in the United Kingdom","volume":"18","author":"Carrieri","year":"2016","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A\u00a0population-based study of genes previously implicated in breast cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13073-022-01052-8","article-title":"Breast cancer risks associated with missense variants in breast cancer susceptibility genes","volume":"14","author":"Dorling","year":"2022","journal-title":"Genome Med"},{"issue":"12","key":"10.1016\/j.gim.2023.100870_bib30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J\u00a0Med Genet"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib32","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10689-021-00278-6","article-title":"Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant","volume":"21","author":"Laitman","year":"2022","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/B:BREA.0000010697.49896.03","article-title":"Excess risk for contralateral breast cancer in CHEK2\u22171100delC germline mutation carriers","volume":"83","author":"Broeks","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","article-title":"Risk for contralateral breast cancer among carriers of the CHEK2\u22171100delC mutation in the WECARE study","volume":"98","author":"Mellemkjaer","year":"2008","journal-title":"Br J Cancer"},{"issue":"35","key":"10.1016\/j.gim.2023.100870_bib35","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2\u22171100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.gim.2023.100870_bib36","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/jnci\/djaa031","article-title":"Radiation treatment, ATM, BRCA1\/2, and CHEK2\u22171100delC pathogenic variants and risk of contralateral breast cancer","volume":"112","author":"Reiner","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ijc.11384","article-title":"CHEK2 1100delC is not a risk factor for male breast cancer population","volume":"108","author":"Syrj\u00e4koski","year":"2004","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.32106","article-title":"Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy","volume":"145","author":"Rizzolo","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12885-017-3631-8","article-title":"CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population","volume":"17","author":"Hallamies","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","article-title":"Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results","volume":"161","author":"Pritzlaff","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40291-018-0344-x","article-title":"Association between CHEK2\u22171100delC and breast cancer: A systematic review and meta-analysis","volume":"22","author":"Liang","year":"2018","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/ejhg.2013.85","article-title":"CHEK2\u22171100delC homozygosity in the Netherlands\u2014prevalence and risk of breast and lung cancer","volume":"22","author":"Huijts","year":"2014","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"10.1016\/j.gim.2023.100870_bib43","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/jmedgenet-2011-100380","article-title":"CHEK2\u22171100delC homozygosity is associated with a high breast cancer risk in women","volume":"48","author":"Adank","year":"2011","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.gim.2023.100870_bib44","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","article-title":"Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2","volume":"8","author":"Bychkovsky","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","article-title":"High risk of breast cancer in women with biallelic pathogenic variants in CHEK2","volume":"180","author":"Rainville","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jmedgenet-2018-105824","article-title":"Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype","volume":"57","author":"Paperna","year":"2020","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.gim.2023.100870_bib47","article-title":"Two unrelated cases with biallelic CHEK2 variants: a novel condition with constitutional chromosomal instability?","author":"Bottillo","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib48","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1086\/375121","article-title":"The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype","volume":"72","author":"Meijers-Heijboer","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2005.05.5160","article-title":"Increased risk of breast cancer associated with CHEK2\u22171100delC","volume":"25","author":"Weischer","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.gim.2023.100870_bib50","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased risk for other cancers in addition to breast cancer for CHEK2\u22171100delC heterozygotes estimated from the Copenhagen general population study","volume":"34","author":"N\u00e4slund-Koch","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.gim.2023.100870_bib51","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1002\/ijc.25003","article-title":"CHEK2 mutations and HNPCC-related colorectal cancer","volume":"126","author":"Suchy","year":"2010","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ejca.2008.09.022","article-title":"The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population","volume":"45","author":"Kleibl","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.ejhg.5201734","article-title":"Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?","volume":"15","author":"Cybulski","year":"2007","journal-title":"Eur J Hum Genet"},{"issue":"17","key":"10.1016\/j.gim.2023.100870_bib54","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ejca.2011.03.025","article-title":"Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility","volume":"47","author":"Xiang","year":"2011","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/gutjnl-2012-304121","article-title":"Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence","volume":"63","author":"Ma","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gim.2023.100870_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2017.05.045","article-title":"Colorectal cancer risk associated with the CHEK2 1100delC variant","volume":"83","author":"Katona","year":"2017","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib57","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.7314\/APJCP.2012.13.5.2051","article-title":"The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib58","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1086\/346094","article-title":"Mutations in CHEK2 associated with prostate cancer risk","volume":"72","author":"Dong","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib59","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Isaacsson Velho","year":"2018","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib61","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib62","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1158\/0008-5472.CAN-04-0341","article-title":"A\u00a0novel founder CHEK2 mutation is associated with increased prostate cancer risk","volume":"64","author":"Cybulski","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/pros.23505","article-title":"A\u00a0comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer","volume":"78","author":"Wu","year":"2018","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib64","first-page":"15708","article-title":"CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib66","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70449-5","article-title":"Prevalence of pathogenic variants in DNA damage response and repair genes in patients undergoing cancer risk assessment and reporting a personal history of early-onset renal cancer","volume":"10","author":"Hartman","year":"2020","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/cancers13030470","article-title":"Incidence of the CHEK2 germline mutation and its impact on clinicopathological features, treatment responses, and disease course in patients with papillary thyroid carcinoma","volume":"13","author":"G\u0105sior-Perczak","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13053-015-0030-5","article-title":"The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population","volume":"13","author":"Kaczmarek-Ry\u015b","year":"2015","journal-title":"Hered Cancer Clin Pract"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib70","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.29426","article-title":"CHEK2 mutations and the risk of papillary thyroid cancer","volume":"137","author":"Sio\u0142ek","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13053-022-00211-7","article-title":"CHEK2 mutations and papillary thyroid cancer: correlation or coincidence?","volume":"20","author":"Koen","year":"2022","journal-title":"Hered Cancer Clin Pract"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib72","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10689-006-7850-4","article-title":"Low frequency of CHEK2 mutations in familial pancreatic cancer","volume":"5","author":"Bartsch","year":"2006","journal-title":"Fam Cancer"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/gim.2017.85","article-title":"Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history","volume":"20","author":"Chaffee","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib74","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1158\/1055-9965.EPI-15-0455","article-title":"Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients","volume":"25","author":"Hu","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib75","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ijc.30116","article-title":"Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer?","volume":"139","author":"Lener","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib76","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4143\/crt.2016.217","article-title":"The prevalence of founder mutations among individuals from families with familial pancreatic cancer syndrome","volume":"49","author":"Lener","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib77","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ijc.32127","article-title":"Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma","volume":"145","author":"Obazee","year":"2019","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib78","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-012-9599-2","article-title":"The risk of gastric cancer in carriers of CHEK2 mutations","volume":"12","author":"Teodorczyk","year":"2013","journal-title":"Fam Cancer"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib79","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1182\/blood.V99.8.3075","article-title":"Mutations of Chk2 in primary hematopoietic neoplasms","volume":"99","author":"Hangaishi","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2011.049494","article-title":"A\u00a0risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations","volume":"97","author":"Janiszewska","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/jid.2011.303","article-title":"CHEK2\u22171100delC and risk of malignant melanoma: Danish and German studies and meta-analysis","volume":"132","author":"Weischer","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib82","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jdv.16729","article-title":"Skin cancer risk in CHEK2 mutation carriers","volume":"35","author":"Bui","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/dna.2008.0781","article-title":"CHEK2 I157T and endometrial cancer","volume":"28","author":"Konstantinova","year":"2009","journal-title":"DNA Cell Biol"},{"issue":"11","key":"10.1016\/j.gim.2023.100870_bib84","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","article-title":"Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort","volume":"29","author":"Ring","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.gim.2023.100870_bib85","article-title":"Identification of genetic risk factors for familial urinary bladder cancer: an exome sequencing study","volume":"5","author":"Pemov","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib86","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10689-020-00190-5","article-title":"Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue","volume":"20","author":"Ni","year":"2021","journal-title":"Fam Cancer"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib87","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamaoncol.2018.6477","article-title":"Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors","volume":"5","author":"AlDubayan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib88","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/carcin\/bgn044","article-title":"Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers","volume":"29","author":"Cybulski","year":"2008","journal-title":"Carcinogenesis"},{"issue":"15","key":"10.1016\/j.gim.2023.100870_bib89","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/hmg\/ddm127","article-title":"Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study","volume":"16","author":"Brennan","year":"2007","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of breast and ovarian cancers with predisposition genes identified by large-scale sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib91","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib92","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4149\/neo_2011_05_392","article-title":"Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma","volume":"58","author":"Havranek","year":"2011","journal-title":"Neoplasma"},{"issue":"16","key":"10.1016\/j.gim.2023.100870_bib93","doi-asserted-by":"crossref","first-page":"21840","DOI":"10.18632\/oncotarget.8187","article-title":"Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression","volume":"7","author":"Lasorsa","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib94","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jama.2015.10080","article-title":"Integrative clinical sequencing in the management of refractory or relapsed cancer in youth","volume":"314","author":"Mody","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13073-016-0389-6","article-title":"Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations","volume":"8","author":"Oberg","year":"2016","journal-title":"Genome Med"},{"issue":"15","key":"10.1016\/j.gim.2023.100870_bib96","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1158\/1078-0432.CCR-15-2717","article-title":"MultiDimensional ClinOmics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: A report from the Center for Cancer Research","volume":"22","author":"Chang","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib97","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1470-2045(18)30242-0","article-title":"Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort","volume":"19","author":"Waszak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib98","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/jnci\/djaa204","article-title":"Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the Children\u2019s Oncology Group","volume":"113","author":"Li","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib99","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1038\/s41598-021-84502-4","article-title":"Prevalence of germline pathogenic variants in 22 cancer susceptibility genes in Swedish pediatric cancer patients","volume":"11","author":"von Stedingk","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib100","doi-asserted-by":"crossref","first-page":"pkab007","DOI":"10.1093\/jncics\/pkab007","article-title":"Frequency of pathogenic germline variants in cancer-susceptibility genes in the Childhood Cancer Survivor Study","volume":"5","author":"Kim","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"20","key":"10.1016\/j.gim.2023.100870_bib101","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2018.77.8589","article-title":"Genetic risk for subsequent neoplasms among long-term survivors of childhood cancer","volume":"36","author":"Wang","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib102","article-title":"Subsequent neoplasm risk associated with rare variants in DNA damage response and clinical radiation sensitivity syndrome genes in the Childhood Cancer Survivor Study","volume":"4","author":"Morton","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.gim.2023.100870_bib103","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35135","article-title":"Companion tumor sequencing to assess the clinical significance of germline sequencing in children with cancer","volume":"4","author":"Mutetwa","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.gim.2023.100870_bib104","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A\u00a0mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gim.2016.147","article-title":"Genetic modifiers of CHEK2\u22171100delC-associated breast cancer risk","volume":"19","author":"Muranen","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib106","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1038\/s41467-020-19966-5","article-title":"The role of polygenic risk and susceptibility genes in breast cancer over the course of life","volume":"11","author":"Mars","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.gim.2023.100870_bib107","article-title":"Comprehensive breast cancer risk assessment for CHEK2 and ATM pathogenic variant carriers incorporating a polygenic risk score and the Tyrer-Cuzick model","volume":"5","author":"Gallagher","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib108","series-title":"National Institute for Health and Care Excellence (NICE). 2019 Exceptional Surveillance of Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer (NICE Guideline Cg164)","year":"2019"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib109","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41436-018-0418-5","article-title":"The illusion of polygenic disease risk prediction","volume":"21","author":"Wald","year":"2019","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib111","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.gim.2021.10.015","article-title":"Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank","volume":"24","author":"Wang","year":"2022","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib112","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.gim.2021.11.016","article-title":"Diversity in cancer genomics research is a matter of equity and scientific discovery","volume":"24","author":"Pal","year":"2022","journal-title":"Genet Med"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib113","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMsr1809937","article-title":"The \u201cAll of Us\u201d research program","volume":"381","author":"Denny","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib114","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41588-019-0394-y","article-title":"Genetics for all","volume":"51","year":"2019","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2021.04.013","article-title":"Combined effect of a polygenic risk score and rare genetic variants on prostate cancer risk","volume":"80","author":"Darst","year":"2021","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.gim.2023.100870_bib116","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1200\/JCO.20.01992","article-title":"Risk of breast cancer among carriers of pathogenic variants in breast cancer predisposition genes varies by polygenic risk score","volume":"39","author":"Gao","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib117","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1055-9965.EPI-20-1319","article-title":"CanRisk Tool-A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants","volume":"30","author":"Carver","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib118","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1399-0004.2008.01111.x","article-title":"Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention","volume":"75","author":"Cybulski","year":"2009","journal-title":"Clin Genet"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13058-022-01507-1","article-title":"Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes","volume":"24","author":"Wei","year":"2022","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.gim.2023.100870_bib120","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.30498","article-title":"A\u00a0study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys","year":"2017","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib121","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk\u00a0genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib122","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12032-013-0828-9","article-title":"Development of breast tumors in CHEK2, NBN\/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele","volume":"31","author":"Suspitsin","year":"2014","journal-title":"Med Oncol"},{"issue":"11","key":"10.1016\/j.gim.2023.100870_bib123","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","article-title":"The context-specific role of germline pathogenicity in tumorigenesis","volume":"53","author":"Srinivasan","year":"2021","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-004-3778-2","article-title":"Pathology of breast cancer in women with constitutional CHEK2 mutations","volume":"90","author":"Huzarski","year":"2005","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13058-016-0758-5","article-title":"Patient survival and tumor characteristics associated with CHEK2:p.I157T \u2013 findings from the Breast Cancer Association Consortium","volume":"18","author":"Muranen","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib126","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10549-011-1635-7","article-title":"Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer","volume":"132","author":"Domagala","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.gim.2023.100870_bib127","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4149\/neo_2012_079","article-title":"CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients","volume":"59","author":"Angelova","year":"2012","journal-title":"Neoplasma"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib128","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/1055-9965.EPI-18-1102","article-title":"Frequency of pathogenic germline variants in CDH1, BRCA2, CHEK2, PALB2, BRCA1, and TP53 in sporadic lobular breast cancer","volume":"28","author":"Petridis","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ijc.20638","article-title":"Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients","volume":"113","author":"Kilpivaara","year":"2005","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.gim.2023.100870_bib130","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and tumor subtype-specific breast cancer risk estimates for CHEK2\u22171100delC carriers","volume":"34","author":"Schmidt","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib131","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-015-1880-y","article-title":"Genomic profiling of CHEK2\u22171100delC-mutated breast carcinomas","volume":"15","author":"Massink","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib132","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-014-2865-2","article-title":"Survival from breast cancer in patients with CHEK2 mutations","volume":"144","author":"Huzarski","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.gim.2023.100870_bib133","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmg.2004.019737","article-title":"Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2\u22171100delC variant","volume":"41","author":"de Bock","year":"2004","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib134","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","article-title":"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2\u22171100delC germline mutation","volume":"25","author":"Schmidt","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.radonc.2006.12.002","article-title":"Breast cancer in patients carrying a germ-line CHEK2 mutation: outcome after breast conserving surgery and adjuvant radiotherapy","volume":"82","author":"Meyer","year":"2007","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.gim.2023.100870_bib136","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2014.306","article-title":"Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy","volume":"111","author":"Kriege","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.gim.2023.100870_bib137","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/ijc.33272","article-title":"Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland","volume":"147","author":"Woko\u0142orczyk","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib138","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2019.01.050","article-title":"Germline DNA repair gene mutations in young-onset prostate cancer cases in the UK: evidence for a more extensive genetic panel","volume":"76","author":"Leongamornlert","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib139","doi-asserted-by":"crossref","first-page":"pkz027","DOI":"10.1093\/jncics\/pkz027","article-title":"The landscape of somatic genetic alterations in breast cancers from CHEK2 germline mutation carriers","volume":"3","author":"Mandelker","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"18","key":"10.1016\/j.gim.2023.100870_bib140","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib141","article-title":"Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer","volume":"4","author":"Greville-Heygate","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib142","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12885-015-1203-3","article-title":"Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer","volume":"15","author":"Liu","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib143","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10549-014-3206-1","article-title":"Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers","volume":"148","author":"Pfeifer","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1016\/j.gim.2023.100870_bib144","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1200\/JCO.20.02151","article-title":"TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib145","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr1668","article-title":"Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study","volume":"9","author":"Broeks","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"22","key":"10.1016\/j.gim.2023.100870_bib146","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib147","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.gim.2023.100870_bib148","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1200\/JCO.2016.68.6725","article-title":"Multigene panels to evaluate hereditary cancer risk: reckless or relevant?","volume":"34","author":"Hall","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.gim.2023.100870_bib149","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jnci\/djx265","article-title":"Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women","volume":"110","author":"Manchanda","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib150","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","article-title":"CHEK2\u22171100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls","volume":"26","author":"Weischer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.gim.2023.100870_bib151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GIM.0b013e318184137c","article-title":"The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group","volume":"11","author":"Teutsch","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2023.100870_bib152","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jss.2020.06.029","article-title":"Expectations of surveillance for non-BRCA gene mutation carriers at increased risk for breast cancer","volume":"256","author":"Caskey","year":"2020","journal-title":"J\u00a0Surg Res"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib153","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","article-title":"Breast cancer screening\u00a0strategies for women with ATM, CHEK2, and PALB2\u00a0pathogenic variants: a comparative modeling analysis","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.gim.2023.100870_bib154","series-title":"German guideline program in oncology. Evidence-Based Guideline for the Early Detection, Diagnosis, Treatment and Follow-Up of Breast Cancer. Version 4.4","year":"2021"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10689-018-0070-x","article-title":"Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk","volume":"17","author":"West","year":"2018","journal-title":"Fam Cancer"},{"issue":"4","key":"10.1016\/j.gim.2023.100870_bib156","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.6400","article-title":"Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer","volume":"6","author":"Kurian","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib157","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","article-title":"Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers","volume":"182","author":"Cragun","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.gim.2023.100870_bib158","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.gim.2022.08.027","article-title":"An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes","volume":"24","author":"Breen","year":"2022","journal-title":"Genet Med"},{"issue":"8","key":"10.1016\/j.gim.2023.100870_bib160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41436-021-01172-3","article-title":"ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)","volume":"23","author":"Miller","year":"2021","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib161","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/gim.2012.176","article-title":"American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: Ethical and policy issues in genetic testing and screening of children","volume":"15","author":"Ross","year":"2013","journal-title":"Genet Med"},{"issue":"29","key":"10.1016\/j.gim.2023.100870_bib162","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1200\/JCO.2006.06.6100","article-title":"Cancer genetic testing and assisted reproduction","volume":"24","author":"Offit","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.gim.2023.100870_bib163","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.296.22.2727","article-title":"Preimplantation genetic diagnosis for cancer syndromes: a new challenge for preventive medicine","volume":"296","author":"Offit","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.gim.2023.100870_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103201","article-title":"Preimplantation genetic testing for carriers of BRCA1\/2 pathogenic variants","volume":"157","author":"Vukovi\u0107","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/gim.0b013e31822ddc7e","article-title":"High-risk consumers\u2019 perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis","volume":"14","author":"Quinn","year":"2012","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib166","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10689-013-9685-0","article-title":"Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes","volume":"13","author":"Rich","year":"2014","journal-title":"Fam Cancer"},{"issue":"2","key":"10.1016\/j.gim.2023.100870_bib167","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","article-title":"BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface","volume":"110","author":"Lee","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.gim.2023.100870_bib168","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","article-title":"The impact of coding germline variants on contralateral breast cancer risk and survival","volume":"110","author":"Morra","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"9","key":"10.1016\/j.gim.2023.100870_bib169","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Onocl"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360023008833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360023008833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:57:47Z","timestamp":1761098267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360023008833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":166,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1098360023008833"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2023.100870","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2023.100870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100870"}}